-

Kinaxis to Bolster Supply Chain Operations of Ono Pharmaceutical

Kinaxis provides end-to-end supply chain orchestration platform to support Ono Pharmaceutical’s further global growth

OTTAWA, Ontario--(BUSINESS WIRE)--Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced Ono Pharmaceutical Co., Ltd.’s adoption of Kinaxis to help orchestrate full visibility and transparency across its global supply chain.

Ono Pharmaceutical Co., Ltd., (ONO) headquartered in Osaka, Japan, is an R&D-oriented pharmaceutical company committed to creating innovative medicines in specific areas. ONO focuses its research on oncology, immunology, neurology and specialty research with high medical needs as priority areas for discovery and development of innovative medicines. ONO has multiple subsidiaries and manufacturing facilities in Japan and overseas and is currently expanding its overseas business with the goal of a becoming a global specialty pharma.

Kinaxis Maestro™, the AI-infused supply chain orchestration platform, will drive operational efficiencies for ONO, empowering the company to expand and diversify its broad portfolio of life-saving drugs. The transformation comes at a time when ONO is preparing for an increase of direct sales in the US and Europe.

“Under the corporate philosophy ‘Dedicated to the Fight against Disease and Pain,’ ONO continues to contribute to and work toward the realization of a sustainable society through the generation of innovative drugs,” said Akira Takada, corporate executive officer, executive director, CMC & production at Ono Pharmaceutical Co., Ltd. “Kinaxis will play an important role in bolstering the supply chain efficiency required to ensure a stable delivery of medicines ONO creates across a broad range of therapeutic areas to patients worldwide.”

“The need for agility-driven transformation to meet challenges and drive business success is imperative in today’s uncertain world,” said Toshiya Kaneko, president at Kinaxis Japan. “With Kinaxis, ONO will be empowered to plan for any scenario, making them more resilient to whatever comes around the corner and bolstering their mission of delivering life-saving drugs to their patients.”

With the addition of ONO to its growing customer base, Kinaxis continues to cement its footprint within the life sciences industry, which provides the brand-name and generic medicines that countless patients rely on. Managing supply chain complexities in biotechnology, cell and gene therapy, medical devices, over-the-counter medicines and more, Kinaxis customers include some of the world's top pharma companies such as Dr. Reddy's, Jamieson Wellness, Merck, Novartis, Siemens Healthineers and Servier.

To learn more about Kinaxis and its supply chain management solutions, please visit Kinaxis.com.

About Kinaxis
Kinaxis is a global leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them, in service of humanity. Our powerful, AI-infused supply chain orchestration platform, Maestro™ , combines proprietary technologies and techniques that provide full transparency and agility across the entire supply chain — from multi-year strategic planning to last-mile delivery. We are trusted by renowned global brands to provide the agility and predictability needed to navigate today’s volatility and disruption. For more news and information, please visit kinaxis.com or follow us on LinkedIn.

Contacts

Media Relations
Jaime Cook | Kinaxis
jcook@kinaxis.com
289-552-4640

Investor Relations
Rick Wadsworth | Kinaxis
rwadsworth@kinaxis.com
613-907-7613

Kinaxis Inc.

TSX:KXS


Contacts

Media Relations
Jaime Cook | Kinaxis
jcook@kinaxis.com
289-552-4640

Investor Relations
Rick Wadsworth | Kinaxis
rwadsworth@kinaxis.com
613-907-7613

Social Media Profiles
More News From Kinaxis Inc.

Kinaxis Introduces Maestro Agent Studio, Unlocking Next Level Decision Making Through Composable AI Agents

OTTAWA, Ontario--(BUSINESS WIRE)--Kinaxis® Inc. (TSX: KXS), the leader in supply chain orchestration, today announced Maestro Agent Studio, making the next phase of its AI agent strategy available to customers following the launch of prebuilt Maestro Agents. Maestro Agent Studio gives supply chain teams a no-code way to compose AI agents grounded in their real operating context, using the same data, workflows, and tools planners already rely on, so agents drive real-world outcomes. Built into t...

Kinaxis Inc. to Host Fourth Quarter 2025 Financial Results Conference Call on March 5, 2026

OTTAWA, Ontario--(BUSINESS WIRE)--Kinaxis® Inc. (TSX:KXS), a global leader in supply chain orchestration, today announced that it has scheduled its conference call to discuss the financial results for its fourth quarter and year ended December 31, 2025. The call will be hosted on Thursday, March 5 at 8:30 a.m. Eastern Time by Razat Gaurav, chief executive officer, and Blaine Fitzgerald, chief financial officer, followed by a question and answer period. The Company will report its financial resu...

Kinaxis Announces Intention to Maximize Size of Normal Course Issuer Bid

OTTAWA, Ontario--(BUSINESS WIRE)--Kinaxis® Inc. (“Kinaxis” or the “Company”) (TSX: KXS) today announces that it intends to amend its current normal course issuer bid (the “NCIB”) to increase the number of its common shares (the “Shares”) that may be repurchased from 1,403,042, representing 5% of the Company’s issued and outstanding Shares as at October 31, 2025, to approximately 2,799,843, representing 10% of the Company’s “public float” as at October 31, 2025, which is the maximum allowable un...
Back to Newsroom